PARD (Poniard Pharmaceuticals) FCF Margin %: 0.00% (As of Sep. 2011)


What is Poniard Pharmaceuticals FCF Margin %?

Poniard Pharmaceuticals PARD FCF Margin % is 0.00% as of Sep. 2011.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Poniard Pharmaceuticals's Free Cash Flow for the three months ended in Sep. 2011 was $-1.71 Mil. Poniard Pharmaceuticals's Revenue for the three months ended in Sep. 2011 was $0.00 Mil. Therefore, Poniard Pharmaceuticals's FCF Margin % for the quarter that ended in Sep. 2011 was 0.00%.

As of today, Poniard Pharmaceuticals's current FCF Yield % is 0.00%.

The historical rank and industry rank for Poniard Pharmaceuticals's FCF Margin % or its related term are showing as below:


PARD's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -84.65
* Ranked among companies with meaningful FCF Margin % only.

Poniard Pharmaceuticals FCF Margin % Related Terms

Poniard Pharmaceuticals FCF Margin % Historical Data

* Premium members only.

The historical data trend for Poniard Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals FCF Margin % Chart

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PARD vs OBMP, NSPX, ATRX: FCF Margin % Comparison

For the Biotechnology subindustry, Poniard Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Poniard Pharmaceuticals FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poniard Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Poniard Pharmaceuticals's FCF Margin % falls into.


Poniard Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Poniard Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2010 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2010 )/Revenue (A: Dec. 2010 )
=-24.283/0
= %

Poniard Pharmaceuticals's FCF Margin for the quarter that ended in Sep. 2011 is calculated as

FCF Margin=Free Cash Flow (Q: Sep. 2011 )/Revenue (Q: Sep. 2011 )
=-1.708/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Poniard Pharmaceuticals (PARD) has a FCF Margin % of 0.00% as of Sep. 2011. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Poniard Pharmaceuticals and its competitors.
Is Poniard Pharmaceuticals' FCF Margin % too high?
Poniard Pharmaceuticals' current FCF Margin % is 0.00%.
How does Poniard Pharmaceuticals' FCF Margin % compare to OBMP and NSPX?
Poniard Pharmaceuticals' FCF Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Poniard Pharmaceuticals and its competitors. Poniard Pharmaceuticals's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poniard Pharmaceuticals stock overvalued right now?
Poniard Pharmaceuticals (PARD) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Poniard Pharmaceuticals (PARD), the current FCF Margin % is 0.00% as of Sep. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poniard Pharmaceuticals Business Description

Address 300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.